Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Duvelisib + Rituximab vs R-CHOP in Relapsed/Refractory Follicular Lymphoma
2015-004729-15Phase 2Terminated
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of duvelisib in follicular lymphoma (FL) (2 arms), sponsored by Infinity Pharmaceuticals, Inc. Primary endpoint: Progression-free survival. Started Mar 2016; status: terminated.
02
Drugs
duvelisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2015-004729-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004729-15.